More than 200 people in nine states have reported bleeding or other symptoms associated with exposure to synthetic cannabinoid products containing an anticoagulant agent, including five who died, the Centers for Disease Control and Prevention reported Friday in an update on an outbreak that began in March. Most of the cases were in Illinois, and the rest in Maryland, Florida, Indiana, Kentucky, Missouri, Pennsylvania, Virginia and Wisconsin. Nearly all of the patients have tested positive for brodifacoum, a vitamin K antagonist anticoagulant, which public health officials believe may have been mixed with synthetic cannabinoid products, commonly referred to as synthetic marijuana, K2 or Spice. CDC said health care providers should screen patients presenting with unexplained bleeding and a possible history of synthetic cannabinoid for vitamin K-dependent antagonist coagulopathy, and report possible cases to their local health department, among other recommendations.

Related News Articles

Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response seeks stakeholder input through April 26 on a…
Headline
The Nebraska Hospital Association Research and Educational Foundation has established a disaster relief fund to help hospital employees adversely affected by…
Headline
The Centers for Disease Control and Prevention this week reported more than 15,000 U.S. cases of hepatitis A since 2016.
Headline
The Ebola outbreak in the Democratic Republic of Congo has exceeded 1,000 confirmed or probable cases.
Headline
Nearly 70 organizations, including the AHA, today urged congressional leaders to advance the House-passed Pandemic and All-Hazards Preparedness…
Headline
Historic flooding in parts of the Midwest caused a number of Nebraska hospitals to be inaccessible by ground transportation, the Nebraska Hospital Association…